Wednesday, February 10, 04:46 am IST
| Feedback
Moneycontrol » News Center » Business » Business News

Want more about Business to land in your mailbox?

Set an alert here

Serum Institute of India launches HIB vaccine in India

Published on Thu, Aug 09, 2007 at 19:01   |  Updated at Thu, Aug 09, 2007 at 20:38  |  Source : Moneycontrol.com

Serum Institute of India Ltd, India’s largest vaccine manufacturer announced the launch of its indigenously manufactured low-cost Haemophilus influenza type b conjugate vaccine under the brand name of “HibPRO” in India. HibPRO has been priced at MRP Rs 375/- for a monodose vial. HibPRO is a vaccine with clinically proven efficacy & safety at an affordable price; hence it is a world class vaccine at Indian price.

 

Haemophilus influenza causes infections that are a major cause of morbidity and mortality in young children spreading through droplets. Children below 5 years of age are at highest risk of the disease & is rarely seen after 5 years of age. Every year globally around 3 to 5 lakhs children die due to H. influenza type b disease. HIB vaccines are safe and highly effective.


RSS feed for news
Click here

 

According to Dr. Cyrus Poonawalla, Chairman, Serum Institute of India Ltd.: “HibPRO has undergone series of clinical trials to prove its efficacy and safety in comparison with commercially available Hib conjugate vaccines. With the launch of HibPRO serum can extend the benefits of Pentavalent or Quadravalent vaccines at a very affordable price. These benefits are mainly fewer numbers of injections, lesser pain to the child and protection against multiple diseases such as H. influenza type b, Hepatitis-B, Diphtheria, Pertussis and Tetanus in one injection.” 

 

Sourced From: Adfactors Public Relations Pvt Ltd

CEO Wall See All

Harsh Manglik

Harsh Manglik

Chairman

Accenture India

Accenture India to hire aggressively for select verticals

Vishal Doshi

Vishal Doshi

Managing Director

Shrenju & Company

Shrenuj & Company will project 15% rev rise this yr

MP Taparia

MP Taparia

Chairman

Supreme Petrochemicals

Supreme Petrochemicals expects Rs 2200cr rev in next 1.5yrs

Vineet Nayyar

Vineet Nayyar

Chief Executive Officer

HCL Technologies

HCL Tech plans to merge arms with itself, eyes new spots

WHAT OTHERS LIKE
  • Most Read
  • Most Viewed
24 Hours
7 Days
1 Month
NEWS FROM OUR PARTNERS
©Network 18, 2010. All Rights Reserved